Gene expression of Interleukin-10 and Foxp3 as critical biomarkers in rheumatoid arthritis patients


  • Rakad M. Kh Al-Jumaily
  • Iman I. AL-Sheakli
  • Haidar J. Muhammed
  • Bahaa Abdullah Lafttah Al-Rubaii



Interleukin 10, FOXp3, Rheumatoid arthritis, cytokine gene expression


Introduction and Aim: Forkhead box P3 (FOXP3) and interleukin-10 (IL-10) are the key regulators controlling the activity of Treg cells, which are crucial for maintaining immune tolerance and reducing autoimmune reactions. The objective of this study was to investigate the potential utility of elevated levels of FOXP3 and IL-10 gene expression as a diagnostic indicator in patients with rheumatoid arthritis (RA).


Materials and Methods: The study used quantitative polymerase chain reaction (qPCR) to examine the expression levels of FOXP3 and IL-10 transcripts in whole blood samples from Iraqi patients with rheumatoid arthritis. A group of healthy control subjects were also included in the study.


Results: In blood samples taken from Iraqi patients diagnosed with rheumatoid arthritis, a statistically significant decrease (P 0.01) in the expression levels of the FOXP3 gene and a statistically significant elevation (P  0.01) of IL-10 expression were seen in contrast to the healthy control group.


Conclusion: Rheumatoid arthritis patients in Iraq may benefit from FOXP3 and IL-10 gene expression tests. IL-10 and FOXP3 overexpression promotes T cell and immune system immunoreactivity.

Author Biographies

Rakad M. Kh Al-Jumaily

Department of Biology, College of Science, University of Baghdad, Baghdad, Iraq

Iman I. AL-Sheakli

Department of Orthodontics, University of AL-Farahidi, College of Dentistry, Baghdad, Iraq

Haidar J. Muhammed

Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq

Bahaa Abdullah Lafttah Al-Rubaii

Department of Biology, College of Science, University of Baghdad, Baghdad, Iraq


Mohammed, W. T., Alosami, M.H., Alubadi, A.E. An assessment of serum interleukin-39 in rheumatoid arthritis patients from Iraq. Biomedicine. 2022 Sep 12;42(4):699-702.

Conforti, A., di Cola, I., Pavlych, V., Ruscitti, P., Berardicurti, O., Ursini, F., et al., Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun. Rev. 2021; 20:102735.

Petrovska, N., Prajzlerova, K., Vencovsky, J., Senolt, L., Filkova, M. The preclinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. Autoimmun. Rev. 2021; 20:102797.

van der Helm van Mil, A.H., Verpoort, K.N., Breedveld, F.C., Huizinga, T.W., Toes, R.E., de Vries, R.R. The HLA DRB1 shared epitope alleles are primarily a risk factor for anticyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 2006;54: 117-1121.

Curran, A.M., Naik, P., Giles, J.T., Darrah, E. PAD enzymes in rheumatoid arthritis: Pathogenic effectors and autoimmune targets. Nat. Rev. Rheumatol. 2020;16:301-315.

Dreaj, H.A., Hathal, H.D., Abbas, A.A. Seropositivity of Toxoplasma gondii antibodies in rheumatoid arthritis patients under treatment with TNF-alpha antagonists. Biomedicine. 2022 May 1;42(2):314-317.

Damerau, A., Gaber, T. Modeling rheumatoid arthritis in vitro: From experimental feasibility to physiological proximity. Int. J. Mol. Sci. 2020; 21:7916.

Wu, R., Li, N., Zhao, X., Ding, T., Xue, H., Gao, C., et al., Low-dose interleukin-2: Biology and therapeutic prospects in rheumatoid arthritis. Autoimmun Rev,2020; 19(10):102645.

Derksen, V., Huizinga, T.W.J., van der Woude, D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol, 2017; 39(4):437-446.

Lee, K.H., Ahn, B.S., Cha, D., Jang, W.W., Choi, E., Park, S., et al., Understanding the immunopathogenesis of autoimmune diseases by animal studies using gene modulation: A comprehensive review. Autoimmun Rev, 2020;19(3):102469.

Shi, H., Chi, H. Metabolic Control of Treg Cell Stability, Plasticity, and tissue specific heterogeneity. Front Immunol, 2019; 10:2716.

Hernandez Bello, J., Oregon Romero, E., Vazquez Villamar, M., Garcia Arellano, S., Valle, Y., Padilla Gutierrez, J.R., et al., Aberrant expression of interleukin 10 in rheumatoid arthritis: Relationship with IL10 haplotypes and autoantibodies. Cytokine. 2017; 95:88-96.

Das, S., Banerjee, S., Majumder, S. Immune subversion by Mycobacterium tuberculosis through CCR5 mediated signaling: involvement of IL 10. PLoS One. 2014; 9:92477.

Hassan, M., Neinaa, M., El Bendary, S., Zakaria, S. MicroRNA-146a and Forkhead box protein 3 expressions in nonsegmental vitiligo: an insight into disease pathogenesis. J Egypt Women’s Dermatol Soc. 2019; 16(2):105-111.

Khalaf, Z. A., Jasim, H. M., Mahdi, A. A. FOXP3 and IL 10 overexpression: A novel diagnostic biomarker in Iraqi patients having hyperthyroidism treated with radioactive iodine. Gene Reports, 2021;25, 101384.

Zhang, Y., Zhang, J., Liu, H., He, F., Chen, A., Yang, H., et al., Meta analysis of FOXP3 rs3761548 and rs2232365 genepolymorphism and multiple sclerosis susceptibility. Medicine.2019; 98 (38): e17224.

Livak, K., Schmittgen, T. Analyzing real time PCR data by the comparative CT method. Nature Protocols, 2008;3:1101-1108.

Qin, B., Yang, M., Fu, H., Ma, N., Wei, T., Tang, Q., et al., Body mass index and the risk of rheumatoid arthritis: a systematic review and dose response meta-analysis. Arthritis Res Ther 2015;17(1):86.

Safiri, S., Kolahi, A.A., Hoy, D., Smith, E., Bettampadi, D., Mansournia, M.A., et al., Global, regional, and national burden of rheumatoid arthritis 1990–2017: A systematic analysis of the global burden of disease study 2017. Ann. Rheum. Dis. 2019; 78:1463-1471.

Myasoedova, E., Davis, J., Matteson, E.L., Crowson, C.S. Is the epidemiology of rheumatoid arthritis changing. Results from a population-based incidence study, 1985-2014. Ann. Rheum. Dis. 2020; 79:440-444.

Taylor-Gjevre, R., Nair, B., Jin, S., Quail, J. Geographic variation in incidence and prevalence rates for rheumatoid arthritis in Saskatchewan, Canada 2001–2014. Can. J. Public Health. 2018; 109:427-435.

Parks, C.G., D’Aloisio, A.A., DeRoo, L.A., Huiber, K., Rider, L.G., Miller, F.W., et al., Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood. Ann. Rheum. Dis. 2013;72: 350-356.

Patel, S.L., Prakash, J., Gupta, V. Decreased mRNA expression level of FOXP3 correlates with TNF-alpha in peripheral blood mononuclear cells (PBMCs) from rheumatoid arthritis patients: a case control study. Current Orthopaedic Practice, 2022;33(1):73-80.

Cush, J. J., Splawski, J. B., Thomas, R., Mcfarlin, J. E., Schulze, Koops, H., Davis, L. S., et al., Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis and Rheumatism: Official Journal of the American College of Rheumatology, 1995; 38(1): 96-104.

Asadullah, K., Sterry, W., Volk, H. D. Interleukin 10 therapy-review of a new approach. Pharmacological reviews, 2003; 55(2): 241-269.




How to Cite

M. Kh Al-Jumaily R, I. AL-Sheakli I, J. Muhammed H, Abdullah Lafttah Al-Rubaii B. Gene expression of Interleukin-10 and Foxp3 as critical biomarkers in rheumatoid arthritis patients. Biomedicine [Internet]. 2023 Aug. 30 [cited 2023 Oct. 4];43(4):1183-7. Available from:



Original Research Articles

Plum Analytics